Considering the significant decrease of Dsg-specific Tregs observed in PV patients, the benefit of autologous polyclonal Tregs infusion in PV and PF patients is under investigation in a phase-1 open-label multicenter trial (NCT03239470) [114]. The gene discussed is DSG1; the disease is acquired polycythemia vera.